The donation is dedicated to translational cancer research, meaning applied cancer research in antibody and cell therapies with the aim of improving prognosis and quality of life for today's cancer patients.
The administrative recipient is CREATE Health Translational Cancer Centre, with Carl Borrebaeck, Professor of Immunotechnology, and Kristian Pietras, Professor of Molecular Medicine, as principal investigators. The funding will be allocated over a five-year period and will go to both existing senior researchers and new recruitment.
The research will be carried out in collaboration with the Swiss Cancer Center and EPFL in Lausanne.
"Our collaboration within the L2CancerBridge programme will now further deepen with the research group led by Douglas Hanahan who has been a leader in translational cancer research for many years. This is a once-in-a-lifetime opportunity to pursue immuno-oncology cancer research", says Carl Borrebaeck.
"This is a gratifying announcement for many cancer researchers at Lund University and a confirmation that they are attracting great interest outside the country's borders. International collaborations are necessary to remain at the forefront and attract large grants", says Erik Renström, Vice-Chancellor of Lund University.
Since its establishment in 1986, the Mrs Berta Kamprad Foundation has contributed more than SEK 770 million to cancer research at Lund University and Skåne University Hospital.
For information on the Mrs Berta Kamprad Foundation for the Study and Control of Cancer, see: https://www.frubertakampradsstiftelse.se